舍曲林治疗缺血性脑卒中后中枢性疼痛的对照研究

A CLINICAL CONTROL STUDY OF SERTRALINE IN TREATMENT OF THE PATIENTS WITH CENTRAL PAIN AFTER STROKE

目的:探讨舍曲林(sertraline)治疗缺血性脑卒中后中枢性疼痛的疗效和安全性。方法:将180例缺血性脑卒中后中枢性疼痛患者随机分为舍曲林治疗组和对照组,其中治疗组90例,对照组90例。治疗组给予舍曲林每次50 mg,每日1次。对照组给予复合维生素片,1片/次,3次/日,共治疗4周。分别于治疗第1周、2周、4周使用视觉模拟评分法(visual analogue scale,VAS)评价临床疗效,同时测定疼痛缓解度(pain anesis rate,PAR),并比较两组患者治疗前和治疗后各观察时点的VAS评分和疼痛缓解率。结果:本研究治疗组患者治疗前VAS评分为8.2±1.7分,4周后降到4.0±1.3分,而对照组治疗前VAS评分为8.0±1.5分,4周后为6.3±1.6分,治疗前两组VAS评分无明显差异,治疗后第1、2、4周时治疗组VAS评分较对照组明显降低,具有统计学差异。结论:舍曲林用于治疗缺血性脑卒中后中枢性疼痛效果好,可作为缺血性脑卒中后中枢性疼痛患者的药物治疗选择之一。

Objective： To estimate the efficiency and safety of sertraline in treating patients with central pain after ischemic stroke. Methods： 180 patients with central pain after ischemic stroke were randomized into sertraline group （90 patients） and control group （90 patients）. The patients in sertraline group were given sertraline 50 mg three times per day and control group with placebo one piece three times per day. We assessed efficacy according visual analogue scale （VAS） and pain anesis rate （PAR） at the first week, second week and forth week after treatment. Results： The VAS score in sertraline group was 8.2 ± 1.7 before taking drugs, and the score declined to 4.0±1.3 after 4 weeks. And the VAS score in control group was 8.0± 1.5, and the score was slightly descended to 6.3±1.6 after 4 weeks. Conclusion： Sertraline is effective and could be a significant choice in treatment of oatients with central oain after ischemic stroke.